Yuko Usui

Yuko Usui

Auto-generated profile, based on publicly available information

Yuko Usui

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experimental Design: Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing. Results: Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months. Conclusions: Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA. See related commentary by Jacobsen Skanderup et al., p. 1381

11 December 2021 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YMYoshinobu Matsuda
Yoshinobu Matsuda
TYTakashi Yamaguchi
Takashi Yamaguchi
YMYoshihisa Matsumoto
Yoshihisa Matsumoto
HIHiroto Ishiki
Hiroto Ishiki
YUYuko Usui
Yuko Usui
SZSadamoto Zenda
Sadamoto Zenda
Background: Dyspnea is a common and distressing symptom in patients with cancer. To improve its management, multicenter confirmatory studies are necessary. Research policy would be useful in conducting these studies. Here, we propose a new research policy for the management of dyspnea in patients with cancer. Methods: The first draft was developed by a policy working group of 11 specialists in the field of supportive care or palliative care for dyspnea. Then, a provisional draft was developed after review by a research support group (the Japanese Supportive, Palliative and Psychosocial Care Study Group) and five Japanese scientific societies (Japanese Association of Supportive Care in Cancer, Japanese Society of Medical Oncology, Japanese Society of Palliative Medicine, Japanese Association of Rehabilitation Medicine and Japanese Society of Clinical Oncology), and receipt of public comments. Results: The policy includes the following components of research policy on dyspnea: (i) definition of dyspnea, (ii) scale for assessment of dyspnea, (iii) reason for dyspnea or factors associated with dyspnea and (iv) treatment effectiveness outcomes/adverse events. The final policy (Ver1.0) was completed on 1 March 2021. Conclusions: This policy could help researchers plan and conduct studies on the management of cancer dyspnea.

12 August 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
YUYuko Usui
Yuko Usui
TMTomofumi Miura
Tomofumi Miura
TKTakashi Kawaguchi
Takashi Kawaguchi
KKKazuhiro Kosugi
Kazuhiro Kosugi
YUYuko Uehara
Yuko Uehara
ESEriko Satomi
Eriko Satomi

1 April 2023
Verified
Other
Open access
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Purpose:We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid).Experimental Design:Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing.Results:Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months.Conclusions:Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA.

14 April 2023
Verified
Other
Open access
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Supplementary Table S1 Patient characteristics in patients with 8 oncogene drivers and squamous cell carcinoma Supplementary Table S2 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay Supplementary Table S3 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay in patients only with brain metastasis Supplementary Table S4 Clinical outcomes of patients treated with a genotype-matched therapy who had oncogenic alterations detected by only plasma cfDNA sequencing.

14 April 2023
Verified
Other
Open access
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Supplementary Figure S1. Consort diagram. Supplementary Figure S2. Frequency of the targetable gene alterations detected by plasma cfDNA sequencing (A) and tissue assay (B) in squamous cell carcinoma Supplementary Figure S3. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to patient characteristics. PPA, positive percent agreement. Supplementary Figure S4. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to metastatic site. PPA, positive percent agreement.